细胞免疫治疗概念下跌1.05%，主力资金净流出42股

Core Points - The cell immunotherapy sector experienced a decline of 1.05%, ranking among the top losers in the concept sector as of the market close on October 23 [1] - Major stocks within the sector, such as Rongchang Bio and Shutaishen, saw significant declines, while a few stocks like ST Zhongzhu and ST Biology posted gains [1][3] - The Shenzhen state-owned enterprise reform concept led the market with a gain of 6.62%, while the cell immunotherapy sector was among the bottom performers [1] Market Performance - The cell immunotherapy concept saw a net outflow of 1.027 billion yuan, with 42 stocks experiencing net outflows [1] - Shutaishen led the outflows with a net outflow of 196 million yuan, followed by Rongchang Bio and Huahai Pharmaceutical [1] - Conversely, stocks like Hengrui Medicine and Baipusais were among those with net inflows, receiving 19.604 million yuan and 12.233 million yuan respectively [1] Stock Performance - The top decliners in the cell immunotherapy sector included Shutaishen (-7.52%), Rongchang Bio (-8.31%), and Huahai Pharmaceutical (-2.17%) [2] - Notable gainers in the broader market included ST Zhongzhu (5.21%), ST Biology (2.48%), and ST Bailing (2.19%) [3] - The trading volume and turnover rates varied significantly among the stocks, indicating differing levels of investor interest [2][3]